• Bay 11-7085: NF-κB Activation Inhibitor Guide

  2026-09-10

  Bay 11-7085 is a practical chemical probe for separating NF-κB-dependent inflammation from cell-cycle arrest and apoptosis. This workflow connects TNFα challenge assays with ER-stress neuroinflammation, endometriosis, and pneumococcal meningitis research while emphasizing controls that prevent overinterpreting cytotoxicity as pathway inhibition.

• JSH-23: Mechanistic Guide to NF-κB Inhibition

  2026-09-09

  JSH-23 is an NF-κB inhibitor designed to separate p65 nuclear transcription from upstream IκB degradation. This guide connects its mechanism to inflammation research, PRV biology, assay design, and translational disease models.

• FH1 (Catalog No. B3700) for iHep Maturation

  2026-09-09

  Learn how FH1 (Catalog No. B3700; SKU B3700) can support more functional iPS cell-derived hepatocyte models through increased albumin secretion, higher CYP3A4 levels, and reduced AFP. This scenario-based guide covers assay interpretation, formulation, storage, workflow controls, and practical supplier selection.

• Catalpol in Alzheimer’s Disease: Mechanisms and Evidence

  2026-09-08

  The 2022 review by Chen et al. synthesizes preclinical evidence that catalpol may influence Alzheimer’s disease through anti-inflammatory, antioxidant, antiapoptotic, mitochondrial, and neuroprotective mechanisms. Its main value is an integrated mechanistic framework, while its review design also requires caution when translating heterogeneous cellular and animal findings into clinical expectations.

• FPH1 (BRD-6125) Hepatocyte Proliferation

  2026-09-08

  A practical, scenario-based guide to using FPH1 (BRD-6125), SKU B3701, in primary human hepatocyte culture and iPS-derived hepatocyte workflows. It explains assay design, solvent handling, functional readouts, interpretation, and vendor-selection considerations without overstating evidence.

• 3-Hydroxybutyrate (BHBA) Assay Design

  2026-09-07

  This scenario-based guide explains how 3-hydroxybutyrate (BHBA), SKU M1297, can improve the design and interpretation of metabolic, viability, ferroptosis, and epigenetic cell assays. It connects product specifications with recent ketone-body research while clearly separating BHBA-specific evidence from broader ketone-body findings.

• 7ACC2: A Flux-Centered Guide to Tumor Metabolism

  2026-09-07

  7ACC2 is a monocarboxylate transporter 1 inhibitor that enables compartment-aware analysis of lactate and pyruvate flux. This guide connects its transport pharmacology with the 25-hydroxycholesterol–AMPK–STAT6 biology of tumor-associated macrophages while emphasizing rigorous assay interpretation.

• ML-7 hydrochloride: MLCK Workflow Guide

  2026-09-05

  ML-7 hydrochloride gives cardiovascular researchers a practical way to perturb the cardiac myosin light chain kinase pathway while tracking contractility, cell death, metabolism, and endothelial barrier behavior. This workflow guide connects MLCK-mediated phosphorylation of myosin light chain to time-resolved ischemia/reperfusion assays and troubleshooting decisions.

• FH1: A Functional Maturity Framework for iHeps

  2026-09-04

  FH1 is a small molecule for evaluating functional maturation during iPS cell differentiation to hepatocytes. This article presents an assay-centered framework that connects albumin, CYP3A4, AFP, morphology, and emerging translational gene-control methods without confusing maturation with gene-expression control.

• Ellagic acid for CK2 and Senescence Assays

  2026-09-04

  Ellagic acid provides a practical CK2 perturbation tool for cancer biology research, apoptosis research, and oxidative stress assay design. Its biochemical selectivity, DMSO handling requirements, and compatibility with paired senescent-versus-proliferating workflows make it useful for connecting target engagement with phenotype rather than relying on viability data alone.

• Danazol Rat Models: From Signal to Phenotype

  2026-09-03

  Danazol research is most informative when steroid signaling is connected to whole-animal developmental phenotypes. This article explains how Danazol and Danocrine-based rat models reveal hypothalamic–pituitary–gonadal axis changes, how to select orthogonal assays, and where the 2025 herbal-extract evidence remains preclinical.

• Rapamycin at the mTOR–Microbiome Interface

  2026-09-03

  Rapamycin (Sirolimus) is more than a potent mTOR inhibitor: it is a translational probe for connecting nutrient signaling, immune regulation, cell-state control, mitochondrial disease biology, and gut microbiome interactions. This article examines how to design stronger experiments around mechanism, exposure, phenotype, and pharmacobiomics while positioning Rapamycin as a strategic research tool rather than a one-dimensional pathway reagent.

• NLRP3 S-Acylation Gates Golgi Access

  2026-09-02

  Williams and Peden show that S-acylation of NLRP3 at conserved Cys-130, together with nearby hydrophobic residues and a polybasic region, controls recruitment to the Golgi. Their findings support a model in which nigericin-induced Golgi dysfunction reduces de-acylation and immobilizes NLRP3, linking organelle stress to inflammasome receptor localization.

• Protease Inhibitor Cocktail for OXPHOS Assays

  2026-09-02

  Protect LRPPRC, oxidative phosphorylation proteins, and labile complexes from degradation during cell and tissue extraction. This EDTA-free, DMSO-based formulation is especially useful for Western blotting, co-immunoprecipitation, pull-down, and kinase workflows where metal chelation could compromise the assay.

• HyperPFU™ High-Fidelity DNA Polymerase Guide

  2026-09-01

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suitable for blunt-ended cloning and sequencing workflows, but not for protocols that depend on 3′-A overhangs or preformed sticky ends.

8157 records 7/544 page Previous Next First page 上5页 678910 下5页 Last page